Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease
Research payments
$7,788,440
Through program year 2019, $7,788,440 in research payments was reported against Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease, across 82 payments, paid by Biogen, Inc..
- Paid by
- Biogen, Inc.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
1 row| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2019 | Research | $7,788,440 | 82 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Jason Aldred Spokane, WA Named on 3 payments
- Burt Scott Durham, NC Named on 3 payments
- Holly Shill Phoenix, AZ Named on 3 payments
- Lana Chahine Philadelphia, PA Named on 3 payments
- Dave Shprecher Sun City, AZ Named on 2 payments
- Rajesh Pahwa Kansas City, KS Named on 2 payments
- Tanya Simuni Chicago, IL Named on 2 payments
- Zbignew Wszolek Jacksonville, FL Named on 2 payments
- Natividad Stover Birmingham, AL Named on 2 payments
- Maureen Leehey Lone Tree, CO Named on 2 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.